Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Findings
What do systematic reviews say?
37 questions · 37 findings · 2 reviews · Headline outcomes only
No studies found 4 · 10.8%GRADE not reported 0 · 0%Very low 12 · 32.4%Low 10 · 27%Moderate 11 · 29.7%High 0 · 0%
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted123 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ change from baseline in CFCS total score and CFQ‐R respiratory domain · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
- no estimate extracted1 study · 22 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted391 participantsVery low
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1 study · 391 participantsLow
Summary of findings ‐ Inhaled mannitol vs control (non‐respirable mannitol)
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted1261 participantsLow
Summary of findings ‐ Inhaled mannitol vs placebo
Annual Exacerbation Rates · people with bronchiectasis
Inhaled mannitol showed no clear difference in exacerbations Exacerbation rate per year. compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.92 [0.78, 1.08]1 study · 461 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Hospitalisations Number of participants experiencing one of more hospitalisations. · people with bronchiectasis
Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.61 [0.34, 1.09]1 study · 461 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- OR 0.96 [0.61, 1.51]2 studies · 804 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
All‐cause mortality · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
1 finding from 1 review
- no estimate extracted3 studies · 840 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Symptoms Bronchiectasis Symptoms Questionnaire · people with bronchiectasis
Inhaled mannitol showed no clear difference in symptoms Bronchiectasis Symptoms Questionnaire compared with placebo (moderate certainty).
1 finding from 1 review
- no estimate extracted1 study · 343 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
FEV1 (L) · people with bronchiectasis
Inhaled mannitol showed no clear difference in lung function FEV1 (L) compared with placebo (moderate certainty).
1 finding from 1 review
- MD 0.031 study · 343 participantsModerate
Summary of findings ‐ 400 mg inhaled mannitol vs 50 mg inhaled mannitol
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
- no estimate extracted2 studies · 324 participantsLow